Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 59, Issue 5, Pages 462-474Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2011.09.066
Keywords
cardiac; imaging; noninvasive
Categories
Funding
- NHLBI [HL101060-01]
- Bracco Diagnostics Inc.
- Astellas Pharma US, Inc.
- GE Healthcare
- Siemens Medical Solutions
- Astellas
- Siemens
- Bracco
- Astellas Pharma US Inc.
- LMI
- GE
- Nordion
- GE Healthcare, Pfizer
- AstraZeneca
- Astellas Pharma Inc.
- Abbott Vascular
- Volcano
- Abbott Pharma
- Toshiba America Medical Systems
- Vital Images
- CardioDx
- Merck
- Cardiogenesis
- BD Medical
- Bracco Diagnostics
- Lantheus
- Bayer
- Medrad
- GE Health
- Gilead
- Forest Laboratories
- GE Medical
- Toshiba Medical Imaging
Ask authors/readers for more resources
Objectives This study examined short-term cardiac catheterization rates and medication changes after cardiac imaging. Background Noninvasive cardiac imaging is widely used in coronary artery disease, but its effects on subsequent patient management are unclear. Methods We assessed the 90-day post-test rates of catheterization and medication changes in a prospective registry of 1,703 patients without a documented history of coronary artery disease and an intermediate to high likelihood of coronary artery disease undergoing cardiac single-photon emission computed tomography, positron emission tomography, or 64-slice coronary computed tomography angiography. Results Baseline medication use was relatively infrequent. At 90 days, 9.6% of patients underwent catheterization. The rates of catheterization and medication changes increased in proportion to test abnormality findings. Among patients with the most severe test result findings, 38% to 61% were not referred to catheterization, 20% to 30% were not receiving aspirin, 35% to 44% were not receiving a beta-blocker, and 20% to 25% were not receiving a lipid-lowering agent at 90 days after the index test. Risk-adjusted analyses revealed that compared with stress single-photon emission computed tomography or positron emission tomography, changes in aspirin and lipid-lowering agent use was greater after computed tomography angiography, as was the 90-day catheterization referral rate in the setting of normal/nonobstructive and mildly abnormal test results. Conclusions Overall, noninvasive testing had only a modest impact on clinical management of patients referred for clinical testing. Although post-imaging use of cardiac catheterization and medical therapy increased in proportion to the degree of abnormality findings, the frequency of catheterization and medication change suggests possible undertreatment of higher risk patients. Patients were more likely to undergo cardiac catheterization after computed tomography angiography than after single-photon emission computed tomography or positron emission tomography after normal/nonobstructive and mildly abnormal study findings. (Study of Perfusion and Anatomy's Role in Coronary Artery [CAD] [SPARC]; NCT00321399) (J Am Coll Cardiol 2012; 59: 462-74) (C) 2012 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available